Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 7/2010

01-10-2010 | Research Paper

Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway

Authors: Yoshihiro Tanimori, Masanobu Tsubaki, Yuzuru Yamazoe, Takao Satou, Tatsuki Itoh, Yasuhiro Kidera, Masahi Yanae, Chikako Yamamoto, Junichi Kaneko, Shozo Nishida

Published in: Clinical & Experimental Metastasis | Issue 7/2010

Login to get access

Abstract

The small GTPases of the Ras and Rho families are widely involved in tumorigenesis and metastasis. We recently showed that YM529/ONO-5920, a new developed bisphosphonate, inhibits the mevalonate pathway, is required for the prenylation of the small GTPases. In this study, we investigated whether YM529/ONO-5920 inhibits tumor cell migration, invasion, adhesion, and metastasis in B16BL6 cells, a mouse melanoma cell line. It was found that YM529/ONO-5920 significantly inhibited lung metastasis, cell migration, invasion, and adhesion at concentrations that did not show anti-proliferative effects on B16BL6 cells. YM529/ONO-5920 also inhibited the expression of matrix metalloproteinases (MMPs) and very late antigens (VLAs). Furthermore, YM529/ONO-5920 suppressed Rho activation, but not activation of Ras. The results indicate that YM529/ONO-5920 suppresses the Rho/ROCK pathways, thereby inhibiting B16BL6 cell migration, invasion, adhesion and metastasis. These findings suggest that YM529/ONO-5920 has potential clinical applications for the treatment of tumour cell metastasis.
Literature
1.
2.
Vihinen P, Kähäri VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166CrossRefPubMed
3.
4.
Di Nezza LA, Misajon A, Zhang J et al (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94:1466–1475CrossRefPubMed
5.
Johnsen M, Lund LR, Romer J et al (1998) Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10:667–671CrossRefPubMed
6.
Dalberg K, Eriksson E, Enberg U et al (2000) Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg 24:334–340CrossRefPubMed
7.
Tsubaki M, Matsuoka H, Yamamoto C et al (2007) The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2. Clin Exp Metastasis 24:431–438CrossRefPubMed
8.
Thomas B, Meenhard H (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524–6536CrossRef
9.
Bartolomé RA, Molina-Ortiz I, Samaniego R et al (2006) Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res 66:248–258CrossRefPubMed
10.
Kerkela E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12:109–125CrossRefPubMed
11.
Yoon SO, Shin S, Lee HJ et al (2006) Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther 5:2666–2675CrossRefPubMed
12.
Park CC, Zhang H, Pallavicini M et al (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535CrossRefPubMed
13.
Yee KL, Weaver VM, Hammer DA (2008) Integrin-mediated signalling through the MAP-kinase pathway. IET Syst Biol 2:8–15CrossRefPubMed
14.
Zhou H, Kramer RH (2005) Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem 280:10624–10635CrossRefPubMed
15.
16.
Nishida S, Fujii Y, Yoshioka S et al (2003) A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 73:2655–2664CrossRefPubMed
17.
Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106CrossRefPubMed
18.
Tsubaki M, Kato C, Nishinobo M et al (2008) Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Cancer Sci 99:152–158PubMed
19.
Denoyelle C, Hong L, Vannier JP et al (2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88:1631–1640CrossRefPubMed
20.
Wada A, Fukui K, Sawai Y et al (2006) Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol 44:142–150CrossRefPubMed
21.
Pozo M, Nicolás R, Egido J et al (2006) Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. Eur J Pharmacol 548:53–63CrossRefPubMed
22.
Vincent L, Chen W, Hong L et al (2001) Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 495:159–166CrossRefPubMed
23.
Luan Z, Chase AJ, Newby AC (2003) Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23:769–775CrossRefPubMed
24.
Honma N, Genda T, Matsuda Y et al (2006) MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells. Lab Invest 86:687–696CrossRefPubMed
25.
26.
Kuphal S, Bauer R, Bosserhoff AK (2005) Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24:195–222CrossRefPubMed
27.
Danker K, Mechai N, Lucka L et al (2001) The small Gtpase ras is involved in growth factor-regulated expression of the alpha1 integrin subunit in PC12 cells. Biol Chem 382:969–972CrossRefPubMed
28.
29.
Malaney S, Daly RJ (2001) The ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia 6:101–113CrossRefPubMed
30.
Campbell SL, Khosravi-Far R, Rossman KL et al (1998) Increasing complexity of Ras signaling. Oncogene 17:1395–1413CrossRefPubMed
31.
Whyte DB, Kirschmeier P, Hockenberry TN et al (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459–14464CrossRefPubMed
32.
Blum R, Cox AD, Kloog Y (2008) Inhibitors of chronically active Ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 3:31–47CrossRefPubMed
33.
Hashimoto K, Morishige K, Sawada K et al (2007) Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354:478–484CrossRefPubMed
34.
Suyama E, Wadhwa R, Kawasaki H et al (2004) LIM kinase-2 targeting as a possible anti-metastasis therapy. J Gene Med 6:357–363CrossRefPubMed
35.
Zohrabian VM, Forzani B, Chau Z et al (2009) Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 29:119–124PubMed
36.
Joshi B, Strugnell SS, Goetz JG et al (2008) Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 68:8210–8220CrossRefPubMed
37.
Li B, Zhao WD, Tan ZM et al (2006) Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett 580:4252–4260CrossRefPubMed
38.
Shibayama H, Anzai N, Braun SE et al (1999) H-Ras is involved in the inside-out signaling pathway of interleukin-3-induced integrin activation. Blood 93:1540–1548PubMed
39.
Liu ZJ, Tanaka Y, Fujimoto H et al (1999) A novel role for H-Ras in the regulation of very late antigen-4 integrin and VCAM-1 via c-Myc-dependent and -independent mechanisms. J Immunol 163:4901–4908PubMed
40.
Leabu M, Uniyal S, Xie J et al (2005) Integrin alpha2beta1 modulates EGF stimulation of Rho GTPase-dependent morphological changes in adherent human rhabdomyosarcoma RD cells. J Cell Physiol 202:754–766CrossRefPubMed
Metadata
Title
Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway
Authors
Yoshihiro Tanimori
Masanobu Tsubaki
Yuzuru Yamazoe
Takao Satou
Tatsuki Itoh
Yasuhiro Kidera
Masahi Yanae
Chikako Yamamoto
Junichi Kaneko
Shozo Nishida
Publication date
01-10-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 7/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9342-z

Other articles of this Issue 7/2010

Clinical & Experimental Metastasis 7/2010 Go to the issue

Research Paper

Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma

Research Paper

Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells

Research Paper

Individual and combined soy isoflavones exert differential effects on metastatic cancer progression

Research Paper

CD133+ single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential

Research Paper

Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells

Research Paper

ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits